Methyl Salicylate
CAS 119-36-8
Methyl Salicylate (CAS 119-36-8) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 105 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Label Active Ingredients
Active ingredient and active moiety rows from source drug product labels.
| Product | Ingredient | Active Moiety | Effective |
|---|---|---|---|
| Antispetic | METHYL SALICYLATE LAV5U5022Y |
SALICYLIC ACID | 20260505 |
| New Terocin | METHYL SALICYLATE LAV5U5022Y |
SALICYLIC ACID | 20260505 |
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 1769.6200000000001 nM | 5 | - |
| - | MIC | 1770 ug.mL-1 | 1 | - |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Injection site inflammation | 34 | 135.485 | 10022078 |
| Food intolerance | 34 | 135.221 | 10061958 |
| Urosepsis | 37 | 84.874 | 10048709 |
| Pruritus | 93 | 58.744 | 10037087 |
| Urticaria thermal | 11 | 58.523 | 10061399 |
| Angioedema | 37 | 49.969 | 10002424 |
| Hepatic enzyme increased | 58 | 46.562 | 10060795 |
| Administration site erythema | 10 | 45.423 | 10074796 |
| Hypercholesterolaemia | 23 | 42.264 | 10020603 |
| Dyspepsia | 41 | 41.275 | 10013946 |
| Nail bed tenderness | 8 | 40.154 | 10049268 |
| Anticipatory anxiety | 9 | 35.133 | 10002758 |
| Hypertension | 67 | 35.086 | 10020772 |
| Pulmonary fibrosis | 25 | 32.535 | 10037383 |
| Septic shock | 36 | 32.469 | 10040070 |
| Drug intolerance | 60 | 30.229 | 10061822 |
| Injection site pruritus | 22 | 29.667 | 10022093 |
| Asthma | 38 | 29.478 | 10003553 |
| Pigmentation disorder | 11 | 27.227 | 10062080 |
| Vulvovaginal swelling | 6 | 26.66 | 10071211 |
| Autonomic neuropathy | 8 | 26.579 | 10061666 |
| Vitamin B12 deficiency | 11 | 24.895 | 10047609 |
| Scratch | 11 | 24.027 | 10039737 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TRPA1 Trpa1 |
Agonist | - | 15046718 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| GAULTHERIA PROCUMBENS (WINTERGREEN) LEAF OIL | 29787 | SU | MTHSPL |
| METHYL SALICYLATE | 29787 | SU | MTHSPL |
| methyl salicylate | 29787 | SU | MTHSPL |
| Methyl Salicylate | 29787 | SU | MTHSPL |
| methyl salicylate | 29787 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Methyl Salicylate used for in pharmaceutical contexts?
Methyl Salicylate (CAS 119-36-8) appears in DailyMed active-ingredient label rows, including Antispetic, New Terocin.
What are the known adverse events for Methyl Salicylate?
Methyl Salicylate has 105 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Injection site inflammation, Food intolerance, Urosepsis, Pruritus, Urticaria thermal. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Methyl Salicylate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Methyl Salicylate with EU status "restricted".
What clinical phase is Methyl Salicylate in?
Methyl Salicylate is rendered with ChEMBL max phase 4 (approved).